Masato Iwasaki - Takeda Pharmaceutical Chief Director of Pharmaceutical Sales, Director
| TKPHF Stock | USD 26.06 1.02 4.07% |
Director
Mr. Masato Iwasaki was serving as President of Japan Pharma Business Unit and Director in Takeda Pharmaceutical Company Limited since April 2015. He joined the Company in April 1985. His previous titles include Chief Director of Pharmaceutical Sales and Director of Product Strategy in the Company. since 2015.
| Age | 59 |
| Tenure | 9 years |
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dawn Zier | Prestige Brand Holdings | 55 | |
| Sam Gejdenson | Phibro Animal Health | 70 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| Patricia Allen | Deciphera Pharmaceuticals LLC | 56 | |
| James Bristol | Deciphera Pharmaceuticals LLC | 71 | |
| George Gunn | Phibro Animal Health | 67 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Patrick Walsh | ANI Pharmaceuticals | 57 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Thomas Corcoran | Phibro Animal Health | 71 | |
| Charles Hinkaty | Prestige Brand Holdings | 64 | |
| Carl Johnson | Prestige Brand Holdings | 68 | |
| Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
| Daniel Raynor | ANI Pharmaceuticals | 56 | |
| Sheila Hopkins | Prestige Brand Holdings | 64 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Celeste Clark | Prestige Brand Holdings | 67 | |
| John Martin | Deciphera Pharmaceuticals LLC | 57 | |
| John Byom | Prestige Brand Holdings | 66 | |
| Tracy Marshbanks | ANI Pharmaceuticals | 52 | |
| Dennis Walsh | Deciphera Pharmaceuticals LLC | 50 | |
Management Performance
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rudolf Houten, Acting CFO and Group Financial Controller | ||
| Constantine Saroukos, CFO Director | ||
| Christophe Weber, CEO and President and Representative Director | ||
| Masahiro Sakane, Independent Director | ||
| Seigo Izumo, Chair Board | ||
| Gabriele Ricci, Chief Officer | ||
| Fumio Sudo, Independent Director | ||
| Yorihiko Kojima, Independent Director | ||
| JeanLuc Butel, Independent Director | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Sr Department | ||
| Michel Orsinger, Independent Director | ||
| Shiro Kuniya, Independent Director | ||
| Emiko Azuma, Independent Director | ||
| Christopher OReilly, Global Fin | ||
| Shinji Honda, Sr. Managing Director, Sr. VP, Corporate Strategy Officer and Director | ||
| Toshiyuki Shiga, Independent Director | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller | ||
| Masato Iwasaki, Chief Director of Pharmaceutical Sales, Director | ||
| Yasuhiko Yamanaka, Managing Director of Special Missions and Director | ||
| Andrew Plump, Chief Medical and Scientific Officer and Corporate Officer | ||
| Tokumasa Takeda, IR Contact Officer | ||
| Yoshiaki Fujimori, Independent Director | ||
| Koji Hatsukawa, Independent Director | ||
| Yasuchika Hasegawa, Chairman and CEO |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 75.53 B | |||
| Shares Outstanding | 1.56 B | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 41.35 % | |||
| Price To Earning | 27.54 X | |||
| Price To Book | 0.97 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Takeda Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Takeda Pharmaceutical's short interest history, or implied volatility extrapolated from Takeda Pharmaceutical options trading.
Currently Active Assets on Macroaxis
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Takeda Pink Sheet analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |